<DOC>
	<DOC>NCT01648270</DOC>
	<brief_summary>The purpose of this study is to see how healthy volunteers bodies handle buprenorphine.</brief_summary>
	<brief_title>Disposition Effects of Cyclosporin on Buprenorphine</brief_title>
	<detailed_description>Subjects will be studied on four occasions in the Clinical Research Unit at Washington University School of Medicine. Sessions and drugs are: 1. Intravenous buprenorphine 2. Sublingual buprenorphine 3. Cyclosporine, then intravenous buprenorphine. Subjects then take oral cyclosporine twice daily, until 4. Sublingual buprenorphine; continue oral cyclosporine twice daily for 5 days</detailed_description>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>1850 yr old Good general health with no remarkable medical conditions BMI &lt; 33 Provide informed consent Known history of liver or kidney disease Use of prescription or non prescription medications, herbals or foods known to be metabolized by or affecting CYP3A Females who are pregnant or nursing Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction) Direct physical access to and routine handling of addicting drugs in the regular course of duty (a routine exclusion from studies of drugs with addiction potential)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>buprenorphine concentration-effect (miosis) relationship</keyword>
</DOC>